Total Payments
$5.9M
2024 Payments
$1.6M
Companies
20
Transactions
567
Medicare Patients
62
Medicare Billing
$5,619
Payment Breakdown by Category
Other$3.3M (55.6%)
Consulting$2.3M (39.0%)
Travel$192,217 (3.3%)
Research$120,813 (2.1%)
Food & Beverage$8,550 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $3.2M | 3 | 53.7% |
| Consulting Fee | $2.3M | 147 | 39.0% |
| Travel and Lodging | $192,217 | 136 | 3.3% |
| Unspecified | $120,813 | 89 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $103,808 | 50 | 1.8% |
| Food and Beverage | $8,550 | 140 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,522 | 1 | 0.1% |
| Honoraria | $240.00 | 1 | 0.0% |
Payments by Type
General
$5.8M
478 transactions
Research
$120,813
89 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Asklepios Biopharmaceutical Inc. | $2.8M | 2 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $1.8M | 17 | $0 (2024) |
| GENZYME CORPORATION | $519,788 | 348 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $379,189 | 1 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $143,074 | 74 | $0 (2024) |
| Amicus Therapeutics, Inc. | $90,733 | 40 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $77,805 | 20 | $0 (2024) |
| Shire North American Group Inc | $40,221 | 25 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $25,104 | 16 | $0 (2024) |
| Vertex Pharmaceuticals Incorporated | $18,556 | 10 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1.6M | 53 | Asklepios Biopharmaceutical Inc. ($1.3M) |
| 2023 | $1.8M | 80 | Asklepios Biopharmaceutical Inc. ($1.5M) |
| 2022 | $467,446 | 52 | Bayer HealthCare Pharmaceuticals Inc. ($379,189) |
| 2021 | $170,266 | 36 | GENZYME CORPORATION ($116,173) |
| 2020 | $1.5M | 67 | Alnylam Pharmaceuticals Inc. ($1.3M) |
| 2019 | $98,620 | 80 | GENZYME CORPORATION ($47,529) |
| 2018 | $153,225 | 107 | GENZYME CORPORATION ($94,973) |
| 2017 | $122,378 | 92 | Genzyme Corporation ($65,098) |
All Payment Transactions
567 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $6,666.67 | General |
| 12/30/2024 | Asklepios Biopharmaceutical Inc. | — | Acquisitions | Cash or cash equivalent | $1,293,621.29 | General |
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Dividend, profit or other return on investment | $199,834.12 | General |
| 11/30/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,059.00 | General |
| 11/06/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $915.42 | General |
| 10/29/2024 | Amicus Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $11.18 | General |
| 09/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Travel and Lodging | Cash or cash equivalent | $9,803.90 | General |
| Category: FABRY DISEASE | ||||||
| 09/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Travel and Lodging | Cash or cash equivalent | $1,114.63 | General |
| Category: FABRY DISEASE | ||||||
| 09/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Travel and Lodging | Cash or cash equivalent | $351.05 | General |
| Category: FABRY DISEASE | ||||||
| 09/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Food and Beverage | In-kind items and services | $173.12 | General |
| Category: FABRY DISEASE | ||||||
| 09/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Travel and Lodging | Cash or cash equivalent | $87.15 | General |
| Category: FABRY DISEASE | ||||||
| 09/06/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 09/06/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 08/20/2024 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,718.00 | General |
| Category: Genetic Disease | ||||||
| 08/20/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 08/20/2024 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 08/15/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: Rare Disease | ||||||
| 07/11/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $87.76 | General |
| 07/11/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Pompe Disease | ||||||
| 06/25/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,170.00 | General |
| 06/19/2024 | GENZYME CORPORATION | LUMIZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Genetic Disease | ||||||
| 06/17/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Pompe Disease | ||||||
| 06/15/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,908.00 | General |
| 06/13/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $11,363.60 | General |
| 06/13/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $573.93 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease | GENZYME CORPORATION | $83,597 | 5 |
| A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease | GENZYME CORPORATION | $9,717 | 18 |
| Pompe Registry | GENZYME CORPORATION | $5,533 | 13 |
| An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response | GENZYME CORPORATION | $3,000 | 7 |
| A phase 4, open label, prospective study in patients with Pompe disease to evaluate the efficacy and safety of alglucosidase alfa produced at the 4000L scale | GENZYME CORPORATION | $2,775 | 4 |
| ICGG Gaucher Registry | GENZYME CORPORATION | $2,308 | 2 |
| Consulted with European CoWorkers | Pharming Healthcare, Inc. | $2,220 | 2 |
| An open-label, multicenter, multinational extension study of the long-term safety and pharmacokinetics of repeated biweekly infusions of neoGAA in patients with Pompe disease | GENZYME CORPORATION | $2,200 | 9 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrate clinical decline or sub-optimal clinical response | GENZYME CORPORATION | $1,500 | 4 |
| A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale | GENZYME CORPORATION | $1,250 | 1 |
| An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy of avalglucosidase alfa (neoGAA, GZ402666) in patients with infantile-onset Pompe disease tre | GENZYME CORPORATION | $1,148 | 4 |
| Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients | GENZYME CORPORATION | $1,141 | 8 |
| Pompe Disease Registry | GENZYME CORPORATION | $1,000 | 2 |
| GAUCHER REGISTRY | GENZYME CORPORATION | $897.60 | 1 |
| A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment naive patients with late onset Pompe disease | GENZYME CORPORATION | $750.00 | 2 |
| Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. | GENZYME CORPORATION | $655.71 | 3 |
| POMPE REGISTRY | GENZYME CORPORATION | $530.00 | 1 |
| A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-nave | GENZYME CORPORATION | $340.00 | 2 |
| An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naive and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients. | GENZYME CORPORATION | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 15 | 15 | $5,160 | $1,513 |
| 2021 | 2 | 31 | 40 | $8,832 | $2,506 |
| 2020 | 1 | 16 | 19 | $6,536 | $1,601 |
Total Patients
62
Total Services
74
Medicare Billing
$5,619
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $5,160 | $1,513 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 18 | $6,192 | $1,952 | 31.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 15 | 22 | $2,640 | $553.73 | 21.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 19 | $6,536 | $1,601 | 24.5% |
About Priya Kishnani
Priya Kishnani is a Pediatrics healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114001021.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Priya Kishnani has received a total of $5.9M in payments from pharmaceutical and medical device companies, with $1.6M received in 2024. These payments were reported across 567 transactions from 20 companies. The most common payment nature is "Acquisitions" ($3.2M).
As a Medicare-enrolled provider, Kishnani has provided services to 62 Medicare beneficiaries, totaling 74 services with total Medicare billing of $5,619. Data is available for 3 years (2020–2022), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatrics
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 06/06/2012
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1114001021
Products in Payments
- Strensiq (Drug) $123,334
- LUMIZYME (Biological) $93,500
- LUMIZYME (Drug) $91,291
- CERDELGA (Drug) $46,119
- NO PRODUCT DISCUSSED (Drug) $44,908
- NEXVIAZYME (Biological) $30,016
- CEREZYME (Drug) $27,741
- POMBILITI (Drug) $21,830
- STRENSIQ (Biological) $19,740
- CEREZYME (Biological) $17,471
- MYOZYME (Drug) $16,141
- GALAFOLD (Drug) $11,530
- VPRIV (Biological) $10,356
- FABRAZYME (Biological) $4,285
- ELAPRASE (Biological) $2,250
- RUCONEST (Biological) $2,220
- Nityr (Drug) $675.00
- Pombiliti (Drug) $112.96
- POMPE - DISEASE (Drug) $57.19
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Durham
Dwight Koeberl
Pediatrics — Payments: $8.4M
Pediatrics $8.4M
John Sleasman, Md, MD
Pediatrics — Payments: $322,883
Pediatrics $322,883
Edward Smith, Md, MD
Pediatrics — Payments: $195,857
Pediatrics $195,857
Dr. Muhammad Zafar, M.d, M.D
Pediatrics — Payments: $158,957
Pediatrics $158,957
Jennifer Li, Md, MD
Pediatrics — Payments: $55,856
Pediatrics $55,856
Sarah Armstrong, Md, MD
Pediatrics — Payments: $46,142
Pediatrics $46,142